Sunesis Announces Closing of Public Offerings and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 24, 2016 16:05 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of its previously announced underwritten offerings of (i)...
Sunesis Announces Pricing of $25 Million Offering of Securities
October 19, 2016 09:01 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten offerings of (i) 4,935,500 shares of its...
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
October 18, 2016 16:01 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other...
Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference
October 18, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at...
Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin
October 13, 2016 16:05 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to European Medicines Agency (EMA)...
Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062
September 12, 2016 06:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from the Company’s Phase 1A study in healthy volunteers...
Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split
September 07, 2016 14:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...
Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology’s 2nd International Conference on New Concepts in B-Cell Malignancies
September 01, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that a poster detailing preliminary results from the Company’s Phase 1A...
Sunesis to Present at Upcoming Investor Conferences
August 31, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences: ...
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
August 25, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of an article detailing the molecular and pharmacologic...